Stocks
Funds
Screener
Sectors
Watchlists

Latest Tri Locum Partners LP Stock Portfolio

Tri Locum Partners LP Performance:
2025 Q3: 11.23%YTD: 7.23%2024: 23.15%

Performance for 2025 Q3 is 11.23%, and YTD is 7.23%, and 2024 is 23.15%.

About Tri Locum Partners LP and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, Tri Locum Partners LP reported an equity portfolio of $435.1 Millions as of 30 Sep, 2025.

The top stock holdings of Tri Locum Partners LP are JNJ, UTHR, MRK. The fund has invested 12.9% of it's portfolio in JOHNSON & JOHNSON and 11.8% of portfolio in UNITED THERAPEUTICS CORP DEL.

The fund managers got completely rid off TEVA PHARMACEUTICAL INDS LTD (TEVA), ALNYLAM PHARMACEUTICALS INC (ALNY) and VERONA PHARMA PLC (VRNA) stocks. They significantly reduced their stock positions in PRAXIS PRECISION MEDICINES I (PRAX), BIOHAVEN LTD and TARSUS PHARMACEUTICALS INC (TARS). Tri Locum Partners LP opened new stock positions in JOHNSON & JOHNSON (JNJ), UNITED THERAPEUTICS CORP DEL (UTHR) and MERCK & CO INC (MRK). The fund showed a lot of confidence in some stocks as they added substantially to VERA THERAPEUTICS INC (VERA), KORRO BIO INC and AXSOME THERAPEUTICS INC (AXSM).

Tri Locum Partners LP Annual Return Estimates Vs S&P 500

Our best estimate is that Tri Locum Partners LP made a return of 11.23% in the last quarter. In trailing 12 months, it's portfolio return was 10.73%.

New Buys

Ticker$ Bought
johnson & johnson56,150,900
united therapeutics corp del51,222,000
merck & co inc37,506,100
xenon pharmaceuticals inc14,699,000
stevanato group s p a8,572,480
dianthus therapeutics inc7,195,820

New stocks bought by Tri Locum Partners LP

Additions

Ticker% Inc.
vera therapeutics inc188
korro bio inc142
axsome therapeutics inc85.06
abbvie inc61.01
soleno therapeutics inc55.98
ascendis pharma a/s18.41

Additions to existing portfolio by Tri Locum Partners LP

Reductions

Ticker% Reduced
praxis precision medicines i-61.12
biohaven ltd-45.03
tarsus pharmaceuticals inc-32.87
madrigal pharmaceuticals inc-30.75
avadel pharmaceuticals plc-28.55
argenx se-9.17

Tri Locum Partners LP reduced stake in above stock

Sold off

Ticker$ Sold
teva pharmaceutical inds ltd-34,305,100
evolus inc-11,411,500
verona pharma plc-20,483,900
legend biotech corp-6,149,000
inspire med sys inc-19,367,400
alnylam pharmaceuticals inc-29,193,200
nuvalent inc-5,796,740
unitedhealth group inc-18,900,400

Tri Locum Partners LP got rid off the above stocks

Sector Distribution

Tri Locum Partners LP has about 74.2% of it's holdings in Healthcare sector.

Sector%
Healthcare74.2
Others25.8

Market Cap. Distribution

Tri Locum Partners LP has about 38.1% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
MID-CAP26.6
MEGA-CAP26.3
UNALLOCATED25.8
LARGE-CAP11.8
SMALL-CAP9.6

Stocks belong to which Index?

About 51.2% of the stocks held by Tri Locum Partners LP either belong to S&P 500 or RUSSELL 2000 index.

Index%
Others48.8
S&P 50026.3
RUSSELL 200024.9
Top 5 Winners (%)%
avadel pharmaceuticals plc
62.2 %
korro bio inc
51.0 %
MDGL
madrigal pharmaceuticals inc
43.6 %
TARS
tarsus pharmaceuticals inc
39.0 %
argenx se
32.3 %
Top 5 Winners ($)$
MDGL
madrigal pharmaceuticals inc
12.9 M
argenx se
8.5 M
avadel pharmaceuticals plc
5.6 M
korro bio inc
5.5 M
VERA
vera therapeutics inc
4.4 M
Top 5 Losers (%)%
SLNO
soleno therapeutics inc
-16.4 %
Top 5 Losers ($)$
SLNO
soleno therapeutics inc
-6.0 M

Tri Locum Partners LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Tri Locum Partners LP

Tri Locum Partners LP has 18 stocks in it's portfolio. About 83.7% of the portfolio is in top 10 stocks. SLNO proved to be the most loss making stock for the portfolio. MDGL was the most profitable stock for Tri Locum Partners LP last quarter.

Last Reported on: 14 Nov, 2025
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions